FDA names second participant in TEMPO digital health pilot

The FDA selected Cadence as the second participant in its TEMPO digital health pilot, which exempts certain digital health devices from premarket authorization while collecting real-world data tied to a Medicare program to inform future regulation of clinical AI systems.

This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it.